Xeris Pharmaceuticals, a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, agreed to acquire Strongbridge Biopharma, a global commercial-stage biopharmaceutical company, for $267m. "This is a very compelling transaction that will create a scalable and diversified biopharmaceutical company increasingly oriented toward more specialty and rare disease products, positioning us for long-term product development and commercial success," Paul R. Edick, Xeris Chairman and CEO. On August 30, 2021, ISS recommended Xeris shareholders vote for the $267m deal with Strongbridge Biopharma.